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Genetic predisposition to schizophrenia associated with
increased use of cannabis
RA Power1,2, KJH Verweij3, M Zuhair1, GW Montgomery4, AK Henders4, AC Heath5, PAF Madden5, SE Medland4, NR Wray2 and
NG Martin4
Cannabis is the most commonly used illicit drug worldwide. With debate surrounding the legalization and control of use,
investigating its health risks has become a pressing area of research. One established association is that between cannabis use and
schizophrenia, a debilitating psychiatric disorder affecting ~ 1% of the population over their lifetime. Although considerable
evidence implicates cannabis use as a component cause of schizophrenia, it remains unclear whether this is entirely due to
cannabis directly raising risk of psychosis, or whether the same genes that increases psychosis risk may also increase risk of
cannabis use. In a sample of 2082 healthy individuals, we show an association between an individual’s burden of schizophrenia risk
alleles and use of cannabis. This was signiﬁcant both for comparing those who have ever versus never used cannabis
(P= 2.6 × 10−4), and for quantity of use within users (P= 3.0 × 10− 3). Although directly predicting only a small amount of the
variance in cannabis use, these ﬁndings suggest that part of the association between schizophrenia and cannabis is due to a shared
genetic aetiology. This form of gene–environment correlation is an important consideration when calculating the impact of
environmental risk factors, including cannabis use.
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INTRODUCTION
During the last quarter of the 20th century, cannabis use has
increased to become the most widely used illicit drug in the
world.1 It is well established that cannabis use is much higher
among schizophrenic patients than in the general population.2
Cannabis intoxication can lead to an acute transient psychotic
episode and produce short-term exacerbations of pre-existing
psychotic symptoms,3–5 an association that has been conﬁrmed
through the experimental administration of tetrahydrocanna-
binol.6,7 Meta-analyses of prospective studies have found that
cannabis use increases the likelihood of developing a psychotic
illness by a factor of roughly two.8–11 A dose response effect has
been demonstrated,12–14 and use in adolescence has been associ-
ated with the greatest risk.15 Given the large health burden from
schizophrenia and other psychotic disorders,16 the view that
cannabis use is a component cause of schizophrenia has heavily
inﬂuenced discussion over the legislation surrounding cannabis use.
However, the relationship between schizophrenia and cannabis
use may be more complicated than it initially seems. Despite a
clear association between the two, the possibility of reverse
causation has not been entirely excluded. Some small studies have
suggested that it is in fact psychosis that is a risk factor for
cannabis use, as those on a psychotic spectrum are more likely to
experiment with drugs.17,18 The strongest evidence comes from
Ferdinand et al.19 who found that the association was bidirec-
tional, as cannabis-naive children with prodromal psychotic
episodes had greater incidence of later cannabis use. However,
a similarly sized study failed to replicate this ﬁnding.20 There is
also the possibility of attempts by patients at self-medication, as it
has been suggested that cannabis use can reduce negative and
affective symptoms in patients with an established psychotic
disorder.21–23
The issue is further complicated by tentative evidence for
interactions between cannabis use and genetic risk variants for
schizophrenia.24 Schizophrenia is known to be highly heritable
with up to 80% of the variance explained by additive genetic
effects,25 and as sample sizes have increased a growing number of
genetic risk variants have been identiﬁed.26,27 Interactions
between risk variants and cannabis use might explain why some
individuals experience psychosis while others do not. However,
cannabis use itself has been reported to be heritable,28–30
although no genetic risk variants have been identiﬁed.31 It is
unclear to what extent the heritability of cannabis use results from
shared heritability with other behavioural phenotypes such as
schizophrenia predicting its use.
Here we test for such genetic overlap directly, and aim to
discern the direction of causation between cannabis use and
schizophrenia. Within a sample of 2082 healthy individuals, we
tested to see whether polygenic risk scores for schizophrenia
predict cannabis use. Polygenic risk scores reﬂect the cumulative
burden of risk alleles carried by an individual as identiﬁed in a
previous genome-wide association study (GWAS),32 here of 13 833
schizophrenia cases and 18 310 controls.27 Such an association
with cannabis use would suggest that those genetically predis-
posed to schizophrenia use cannabis more frequently. This would
mean that the association between schizophrenia and cannabis
use is not simply one of an environmental risk factor, but
rather involves gene–environment correlation, as individuals
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choose and shape their own environment based on their own
innate preferences.
MATERIALS AND METHODS
The data used in this study come from the Australian Twin Registry. Data
were obtained from two studies in which twins and their families
participated in semi-structured diagnostic telephone interviews aimed
primarily at assessing psychiatric health. Informed consent was obtained
from all participants.
Sample 1 consisted of 6265 individuals aged between 23 and 39 years
(mean= 29.9 ± 2.5) interviewed between 1996 and 2000. Participants were
members of the young adult cohort, a volunteer panel of twins born
between 1964 and 1971. The interview was based on a modiﬁed version of
the SSAGA (Semi-Structured Assessment of the Genetics of Alcoholism33).
Detailed information about the sample recruitment, the study procedure
and the measures can be found elsewhere.34 Sample 2 comprised 9688
individuals aged between 18 and 91 years (mean= 46.3 ± 11.3) interviewed
between 2001 and 2005. Participants were members of the older and
younger adult cohort of Australian twin pairs (born between 1895 and
1964, and between 1964 and 1971, respectively). A subset of this sample
was ascertained based on large sibship size, or having a relative with
nicotine or alcohol dependence. The interview used for this sample was
also based on a modiﬁed version of the SSAGA. Further details about the
sample and assessment can be found in Heath et al.35
A subset of the participants (N= 1866; 11.7%) participated in both
studies, in which case we used data from the last assessment. The
combined phenotypic sample consisted of 14 087 individuals, of whom
7172 were genotyped. In both studies, twins were asked the same items
about cannabis use: (1) did you ever use marijuana?, (2) how old were you
the very ﬁrst time you tried marijuana (not counting the times you took it
as prescribed)? and (3) how many times in your life have you used
marijuana (do not count times when you used a drug prescribed for you
and took the prescribed dose). Ever use was measured on a dichotomous
scale (ever versus never), whereas age at initiation and quantity of use
were open questions. Table 1 shows the prevalence of cannabis use for
individuals included in the present study.
Genotype data were obtained using three different Illumina single nucleotide
polygmorphism (SNP) genotyping platforms (317K, HumanCNV370-
Quadv3, Human CNV370v1 and Human610-Quad). Standard quality control
procedures were applied as outlined previously,36 including checks for
ancestry outliers, Hardy–Weinberg equilibrium (Po10−6), Mendelian errors,
call rate, genotypic missingness (>5%), individual missingness (>5%) and
minor allele frequency (o0.01). Individuals were pruned on relatedness,
removing one individual from each pair with relatedness >0.05, as
determined from genetic data. The ﬁnal sample therefore comprised
2082 ‘unrelated’ individuals (see Table 1 for sample details).
Polygenic risk scores were constructed using the P-values and log10
odds ratios from the most recent large GWAS of schizophrenia, a meta-
analysis of the Psychiatric Genomics Consortium’s studies with additional
Swedish samples totalling 13 833 cases and 18 310 controls.27 SNPs were
pruned for linkage disequilibrium using P-value informed clumping in
PLINK,37 using a cutoff of R2 = 0.25 within 200 kb window. The major
histocompatibility complex region of the genome was excluded, due to its
complex linkage disequilibrium structure. After linkage disequilibrium
pruning, 147 830 SNPs remained. Multiple scores were generated for each
individual using the PLINK score option and based on top SNPs from the
schizophrenia GWAS using varying signiﬁcance thresholds (P= 0.0001,
0.001, 0.01. 0.05, 0.1, 0.2, 0.3, 0.4, 0.5 and 1.0). Polygenic risk scores were
tested for association with a binary ever versus never used cannabis and
two quantitative traits for quantity of use and age at ﬁrst use, in logistic
and linear regressions, respectively. These analyses were corrected for the
ﬁrst 10 ancestry-informative principal components, genotyping platform,
sex, age, age squared and sex by age. Analysis was performed in STATA.38
RESULTS
After pruning, 2082 unrelated individuals remained in our sample
with both genotype and phenotype measures. Within the sample,
1011 individuals (48.6%) had ever used cannabis, of whom 997
had data on quantity of use. Mean number of usages of cannabis
over lifetime was 62.7 (95% CI 53.8–71.6), and the mean age of
initiation of use was 20.1 (95% CI 19.7–20.5). Males showed higher
rates of use than females, 53.5% compared with 43.9% (Po0.001),
although no signiﬁcant difference in age at initiation. Table 1
shows the summary statistics for the sample.
Polygenic risk scores for schizophrenia showed positive
associations for ever versus never use of cannabis across all
P-value thresholds, with the strongest association for those SNPs
with P-values of 0.01 or below in the original schizophrenia GWAS
(see Figure 1, R2 = 0.47%, P= 2.6 × 10− 4). Signiﬁcant associations
were also seen in the analysis of quantity of cannabis use for 9 of
the 10 SNP cutoffs, with the top association seen for those SNPs
with P⩽ 0.05 for schizophrenia (R2 = 0.85%, P= 0.003). No associa-
tion was seen with age at initiation of use, although the
association with quantity of use remained signiﬁcant when
number of years of usage was accounted for (results not shown).
As a secondary analysis, polygenic risk score for schizophrenia
risk alleles with P⩽ 0.01 (the threshold with the greatest
association in the primary analysis) was examined within 990
twin pairs (608 dizygotic and 382 monozygotic) where data on
cannabis use of both twins was available. Taking the mean
polygenic risk score within each twin pair, an ordinal regression
was performed to predict whether neither (n= 272), one (n= 273)
or both twins (n= 445) were cannabis users. After correcting for
age, sex and zygosity, a signiﬁcant association was observed
(P= 0.001). Those twin pairs where both reported using cannabis
had the greatest burden of schizophrenia risk alleles, pairs with
only one user were found to have an intermediate level and the
Table 1. Summary statistics of sample for cannabis use traits
Users Non-users
N 1011 1071
Mean age (s.e.) 41.3 (0.23) 53.0 (0.37)
Percentage female (%) 46.5 56.0
Mean age at initiation (s.e.) 19.6 (0.06) —
Mean number of uses over lifetime (s.e.) 62.7 (4.56) —
Schizophrenia polygene scores and cannabis use
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Figure 1. Results of polygenic risk scores for schizophrenia predict-
ing variance explained (R2) in cannabis use as both a binary trait of
ever versus never, and as a quantitative trait of lifetime use within
only users. Polygenic scores were created using different cutoffs for
the inclusion of risk variants for schizophrenia, ranging from
P= 0.0001 to 1.0.
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lowest burden was found in pairs where neither twin reported use
(see Figure 2).
DISCUSSION
Our results show that to some extent the association between
cannabis and schizophrenia is due to a shared genetic aetiology
across common variants. They suggest that individuals with an
increased genetic predisposition to schizophrenia are both more
likely to use cannabis and to use it in greater quantities. This is not
to say that there is no causal relationship between use of cannabis
and risk of schizophrenia, but it does establish that at least part of
the association may be due to causal relationship in the opposite
direction. Although the variance in cannabis use explained by
schizophrenia polygenic risk scores is small, it is in line with other
cross-phenotype analyses, largely due to the polygenic risk scores
for schizophrenia predicting only ~ 7% of the variation for
schizophrenia itself. Previous associations between polygenic risk
scores for schizophrenia and other psychiatric illnesses, such as
bipolar disorder, major depression and autism,39 have shown
effects of similar sizes. Further research will be needed to see
whether the genetic overlap observed here is speciﬁc to cannabis
use or is present across illicit drug use and addiction phenotypes,
data for which was not widely available in this sample. For now,
these ﬁndings have important implications for the current
perception of cannabis use as a risk factor for schizophrenia,
and other psychotic disorders.
However, it is worth noting that this association, if true, does
not rule out the possibility of cannabis independently being a risk
factor for schizophrenia. A bidirectional association between
cannabis use and psychosis has previously been suggested.40
Further, one caveat to interpreting the direction of causation
concerns the discovery sample used to identify schizophrenia risk
alleles. The schizophrenia GWAS sample will likely include many
more cannabis users among cases than controls. This may lead to
an excess of causal SNPs associated with cannabis use, as opposed
to schizophrenia itself, identiﬁed as schizophrenia risk alleles. Only
if the discovery schizophrenia sample was comprised entirely of
non-cannabis users could causation be inferred without any risk of
confounding. This is an important consideration as to whether
polygenic risk scores overestimate individuals’ un-modiﬁable
genetic risk by including their genetic predisposition to modiﬁable
environmental risk factors.
These results highlight the blurring between behavioural
phenotypes and environment, and have wider implications for
how we perceive supposedly environmental risks for disease.
Individuals select their own environments based on their innate
and learned preferences, and have their environments react to
their own behaviour. Further, parents pass down both genes and
environment to their children. All of these can contribute to
gene–environment correlation, particularly with respect to beha-
vioural traits. Several studies have shown that supposedly environ-
mental risk factors such as urbanicity, religiosity and stressful life
events have heritable components to them.41–43 The existence of
heritability for supposedly environmental risk factors does not
mean they are inevitable, only that causality is more complicated
to discern. Future studies will need to explore the matching of
cases and controls on environmental risk variants to fully
disentangle causation. This can be supplemented exploring the
generation of polygenic risk scores for environmental risk factors,
and their role in predicting disease status. The wider availability of
genetic data in richly phenotyped samples should allow for the
integration of genetics into an epidemiological framework, and so
the discovery of gene–environment correlations where they exist.
With ongoing debate over the legalization of cannabis and the
potential health risks it poses, understanding the association
between its use and schizophrenia is a priority. It has previously
been suggested that, even assuming an entirely causal relation-
ship, the required reduction in the number of cannabis users to
prevent one case of schizophrenia is in the thousands.44
Our ﬁndings here highlight the possibility that this association
might be bidirectional in causation, and that the risks of cannabis
use could be overestimated. This is an important subtlety to
consider when calculating the economic and health impact of
cannabis use.
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